Methamphetamine for Methamphetamine Use

Overseen By Heather Barkholtz, PhD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: University of Wisconsin, Madison

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.

Research Team

Heather K Barkholtz, PhD

Principal Investigator

University of Wisconsin, Madison

David Leinweber, MD

Principal Investigator

University of Wisconsin, Madison

Eligibility Criteria

This trial is for healthy individuals who want to help understand how different forms of methamphetamine work in the body. Participants will be involved in three study visits over a maximum of 12 weeks.

Inclusion Criteria

Good mental health as determined by self-reported responses to the Psychopathology Screener

I don't have major heart, brain, mental health, cancer, hormone, metabolism, kidney, or liver diseases.

English-speaking (able to provide consent and complete questionnaires)

Exclusion Criteria

History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener

Pregnancy or lactation (pregnancy test, if needed)

I cannot stop my current medication for 2 days for study visits.

Treatment Details

Interventions

• 1:1 racemic mixture of two isomers (Central Nervous System Stimulant)
• R-(-)-methamphetamine (Central Nervous System Stimulant)
• S-(+)-methamphetamine (Central Nervous System Stimulant)

Trial Overview The study is testing two mirror-image chemical structures of methamphetamine: R-meth, found in nasal decongestants, and S-meth, used to treat ADD. It aims to compare their effects on metabolism and impairment.

Participant Groups

Group I: S-Meth, R-Meth, Racemic Isomer Experimental Treatment 3 Interventions

First visit: Administer S-Meth, then at least 7 days later Second visit: Administer R-Meth, then at least 7 days later Third visit: Administer (1:1) racemic methamphetamine

Group II: Racemic Isomer, S-Meth, R-Meth Experimental Treatment 3 Interventions

First visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Second visit: Administer S-Meth, then at least 7 days later Third visit: Administer R-Meth

Group III: R-Meth, Racemic Isomer, S-Meth Experimental Treatment 3 Interventions

First visit: Administer R-Meth, then at least 7 days later Second visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Third visit: Administer S-Meth

Who Is Running the Clinical Trial?

University of Wisconsin, Madison

Lead Sponsor

Trials

1,249

Recruited

3,255,000+

U.S. Department of Justice

Collaborator

Trials

23

Recruited

86,700+